留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

喹诺酮类抗菌药不良反应的研究进展

刘倩 张晶 林立敏 卢克鹏 宋洪涛

刘倩, 张晶, 林立敏, 卢克鹏, 宋洪涛. 喹诺酮类抗菌药不良反应的研究进展[J]. 药学实践与服务, 2015, 33(6): 505-507,543. doi: 10.3969/j.issn.1006-0111.2015.06.007
引用本文: 刘倩, 张晶, 林立敏, 卢克鹏, 宋洪涛. 喹诺酮类抗菌药不良反应的研究进展[J]. 药学实践与服务, 2015, 33(6): 505-507,543. doi: 10.3969/j.issn.1006-0111.2015.06.007
LIU Qian, ZHANG Jing, LIN Limin, LU Kepeng, SONG Hongtao. Research progress of adverse drug reaction of quinolone antimicrobial agents[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 505-507,543. doi: 10.3969/j.issn.1006-0111.2015.06.007
Citation: LIU Qian, ZHANG Jing, LIN Limin, LU Kepeng, SONG Hongtao. Research progress of adverse drug reaction of quinolone antimicrobial agents[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 505-507,543. doi: 10.3969/j.issn.1006-0111.2015.06.007

喹诺酮类抗菌药不良反应的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.007

Research progress of adverse drug reaction of quinolone antimicrobial agents

  • 摘要: 喹诺酮类药物自开发以来由于其抗菌谱广、活性强而受到临床欢迎。其常见的不良反应包括:胃肠道紊乱、神经系统反应、皮肤反应等,大多程度轻微且可自愈。但某些品种上市后因严重的毒副作用而撤出市场,应当引起临床高度重视。笔者通过查阅国内外有关文献,总结其不良反应、发生不良反应的高危因素及在特殊人群中的应用,以期为临床合理用药提供参考。
  • [1] Tome AM,Filipe A. Quinolones:review of psychiatric and neurological adverse reactions[J]. Drug Saf,2011,34(6):465-484.
    [2] 张霞光,李天云. 喹诺酮类抗菌药在临床使用中的不良反应[J].国外医药(抗生素分册),2003,24:30-33.
    [3] Kim J,Ohtani H,Tsujimoto M. Quantitative comparison of the convulsive activity of ombinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents[J].Drug Metab Pharmacok,2009,24(2):167-174.
    [4] 陈翠环,潘宁开. 喹诺酮类药物诱发精神症状的回顾性分析[J].实用医技杂志,2008,15(10):1278-1279.
    [5] 操银针. 喹诺酮类药物引起神经系统不良反应358例分析[J].医药导报,2007,26(10):1246-1247.
    [6] Ray WA,Murray KT,Hall,et al. Azithromycin and the risk of cardiovascular death[J].N Engl J Med,2012,366:1881-1890.
    [7] Lapi F,Wilchesky M, Kezouh A,et al. Fluoroquinolones and the risk of serious arrhythmia: a population-based study[J].Clin Infect Dis,2012,55:1457-65.
    [8] Adefurin A,Sammons H,Jacqz-Aigrain E,et al. Ciprofloxacin safety in paediatrics: a systematic review[J].Arch Dis Child,2011,96:874-80.
    [9] Schaad UB. Will fluoroquinolones ever be recommended for common infections in children?[J].Pediatr Infect Dis J,2007,26:865-867.
    [10] Pichichero ME,Arguedas A, Dagan R,et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure[J].Clin Infect Dis, 2005,41:470-478.
    [11] Seeger JD,West WA,Fife D,et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in amanaged care population[J]. Pharmacoepidemiol Drug Safe,2006,15:784-792.
    [12] Wise BL,Peloquin C,Choi H,et al. Impact of age,obesity,and steroiduse on quinolone-associated tendon disorders[J].Am J Med,2012,125:23-28.
    [13] Mandell LA,Ball P,Tillotson G. Antimicrobial safety and toler ability:differences and dilemmas[J].Clin Infect Dis,2001,32(Suppl):72-79.
    [14] Paterson JM,Mamdani MM, Manno M,et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study[J].CMAJ,2012,184:1565-1570.
    [15] Etminan M, Forooghian F,Brophy JM,et al. Oral fluoroquinolones and the risk of retinal detachment[J].JAMA, 201,307:1414-1419.
    [16] Albini TA,Karakousis PC,Abbey AM,et al. Association between oral fluoroquinolones and retinal detachment[J].Am J Ophthalmol, 2012,154:919-921.
    [17] Christ W, Lehnert T,Ulbrich B. Specific toxicologic aspects of the quinolones[J].Rev Infect Dis,1988,10:141-146.
    [18] Kato M,Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats[J].Fundam Appl Toxicol,1988,11 (1):110-119.
    [19] Grady R. Safety profile of quinolone antibiotics in the pediatric population[J].Pediatr Infect Dis,2003,22 (12):1128-1132.
    [20] van der Linden PD, Sturkenboom MC, Herings RM,et al. Fluoroquinolones and risk of achilles tendon disorders:case-control study[J].BMJ,2002, 324(7349):1306-1307.
    [21] Shaughnessy MK,Amundson WH, Kuskowski MA,et al. Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection[J].Infect Control Hosp Epidemiol,2013,34:109-116.
  • [1] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404082
    [2] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [3] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
  • 加载中
计量
  • 文章访问数:  2559
  • HTML全文浏览量:  304
  • PDF下载量:  287
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-03-03
  • 修回日期:  2014-06-26

喹诺酮类抗菌药不良反应的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.007

摘要: 喹诺酮类药物自开发以来由于其抗菌谱广、活性强而受到临床欢迎。其常见的不良反应包括:胃肠道紊乱、神经系统反应、皮肤反应等,大多程度轻微且可自愈。但某些品种上市后因严重的毒副作用而撤出市场,应当引起临床高度重视。笔者通过查阅国内外有关文献,总结其不良反应、发生不良反应的高危因素及在特殊人群中的应用,以期为临床合理用药提供参考。

English Abstract

刘倩, 张晶, 林立敏, 卢克鹏, 宋洪涛. 喹诺酮类抗菌药不良反应的研究进展[J]. 药学实践与服务, 2015, 33(6): 505-507,543. doi: 10.3969/j.issn.1006-0111.2015.06.007
引用本文: 刘倩, 张晶, 林立敏, 卢克鹏, 宋洪涛. 喹诺酮类抗菌药不良反应的研究进展[J]. 药学实践与服务, 2015, 33(6): 505-507,543. doi: 10.3969/j.issn.1006-0111.2015.06.007
LIU Qian, ZHANG Jing, LIN Limin, LU Kepeng, SONG Hongtao. Research progress of adverse drug reaction of quinolone antimicrobial agents[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 505-507,543. doi: 10.3969/j.issn.1006-0111.2015.06.007
Citation: LIU Qian, ZHANG Jing, LIN Limin, LU Kepeng, SONG Hongtao. Research progress of adverse drug reaction of quinolone antimicrobial agents[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 505-507,543. doi: 10.3969/j.issn.1006-0111.2015.06.007
参考文献 (21)

目录

    /

    返回文章
    返回